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Abstract
We studied clinical and radiographic features of interstitial lung disease (ILD) during trimetho-
prim/sulfamethoxazole (TMP/SMX) administration. Ten patients who had received prednisolone
treatment for underlying diffuse pulmonary disease showed various ILDs after introduction of
TMP/SMX. The radiographic features of the ILDs were not consistent with infectious disease or
exacerbation of the underlying disease, and these diagnoses were excluded radiographically and on
clinical grounds during the differential diagnosis of the ILDs. These ILDs emerged relatively early
after introduction of TMP/SMX, which is consistent with the former case report of drug-induced
ILD (DI-ILD) caused by TMP/SMX. Therefore DI-ILDs caused by TMP/SMX were suspected in
these cases. In most of these cases, the ILDs were clinically mild and disappeared immediately
although administration of TMP/SMX was continued.
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We studied clinical and radiographic features of interstitial lung disease (ILD) during trimethoprim/
sulfamethoxazole (TMP/SMX) administration.  Ten patients who had received prednisolone treatment 
for underlying diﬀuse pulmonary disease showed various ILDs after introduction of TMP/SMX.  The 
radiographic features of the ILDs were not consistent with infectious disease or exacerbation of the 
underlying disease,  and these diagnoses were excluded radiographically and on clinical grounds during 
the diﬀerential diagnosis of the ILDs.  These ILDs emerged relatively early after introduction of 
TMP/SMX,  which is consistent with the former case report of drug-induced ILD (DI-ILD) caused by 
TMP/SMX.  Therefore DI-ILDs caused by TMP/SMX were suspected in these cases.  In most of these 
cases,  the ILDs were clinically mild and disappeared immediately although administration of TMP/
SMX was continued.
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nterstitial lung diseases (ILDs) represent a very 
large group of more than 200 diﬀerent entities,  
many of which are rare diseases [1].  Recently,  con-
ventional drugs have emerged as relatively common and 
signiﬁcant inducers of diﬀuse ILD,  as well as of 
pleural and pulmonary vascular disease [2].  These 
kind of drug reactions,  in other words,  drug-induced 
interstitial lung disease (DI-ILD),  constitute one of the 
major diagnostic challenges in pulmonary medicine.  
This is especially the case immunocompromised hosts,  
in whom DI-ILD is estimated to account for 5ｵ to 
30ｵ of all pulmonary complications.  Such reactions 
must be distinguished from the opportunistic infections 
and disease recurrence they mimic both clinically and 
radiographically.  In this setting,  the identiﬁcation of 
a drug-related etiology of a patientʼs disease may be 
diﬃcult because of a lack of speciﬁc clinical,  func-
tional,  or radiographic ﬁndings [3].  The widely 
accepted criteria of DI-ILD are as follows.  First,  
there should be a history of drug exposure.  Secondly,  
the clinical,  imaging,  and pathologic pattern of drug 
involvement should conform to earlier observations 
with the drug.  Thirdly,  etiology of lung disease other 
than drugs should be ruled out.  Fourthly,  improve-
ment should follow discontinuation of the suspected 
drug.  And ﬁnally,  symptoms should recur on rechal-
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lenge [4].  Trimethoprim,  a trimethoxybenzylpyrimi-
dine,  inhibits bacterial dihydrofolic acid reductase 
about 50,000 times more eﬃciently than the same 
enzyme of mammalian cells.  When given together with 
sulfonamides,  trimethoprim produces sequential block-
ing in this metabolic sequence,  resulting in marked 
enhancement of the activity of both drugs.  Infections 
with Pneumocystis jiroveci and some other pathogens can 
be treated orally with high doses of the combination 
(dosed on the basis of the trimethoprim component at 
15-20mg/kg) or can be prevented in immunosup-
pressed patients by one double-strength tablet daily or 
3 times weekly [5].  According to previous reports,  
TMP/SMX would cause ILD,  pulmonary inﬁltration 
with eosinophilia,  pulmonary edema,  or noncardio-
genic pulmonary edema [6-10],  but there have been 
few case reports of DI-ILD caused by TMP/SMX.
　 Here we report ten patients with a range of ILDs 
that were found incidentally by chest CT scans 
obtained during the course of observing the underlying 
disease.
Materials and Methods
　 We studied characteristics of the background,  
clinical course,  and radiographic features of 10 
patients who showed abnormal shadows after the 
administration of TMP/SMX during the treatment of 
the underlying diﬀuse pulmonary diseases.  This study,  
conducted from 2005 to 2008 at the National Hospital 
Organization Sanyou Hospital,  included 4 men and 6 
women with a median age of 71 years (range: 60 to 84 
years).  Seven patients had interstitial pneumonia,  2 
had pulmonary vasculitis,  and one had dermatomyosi-
tis.  Eight patients received TMP/SMX as prophy-
laxis,  and 2 patients received it as treatment.  Table 
1 shows the dose and schedule of TMP/SMX.  
Clinical characteristics of the patients and the time 
course of the abnormal shadow of the lung were 
recorded.  Radiographic characteristics were 
described based on the ﬁndings of CT scanning.  We 
deﬁned ILD as a pulmonary abnormality that can be 
detected by chest CT imaging,  and that showed an 
inﬁltrative shadow in the pulmonary parenchyma.  
Chest CT with an Asteion CT scanner (Toshiba 
Medical Systems Corporation,  Tokyo,  Japan) was 
performed to assess the eﬀect of the treatment on the 
underlying disease.  The images of the patients were 
acquired under the following conditions: collimation 
of 2mm; ﬁeld of view of 200mm; slice intervals of 
0.75s; operation at 120kV; 150mA tube ﬁlament 
current; lung window adjustment; center and width of 
－600 and 1,600HU,  respectively; and image recon-
struction with a 512×512 pixel matrix.  A ﬁlter was 
applied to the high resolution algorithm for image 
reconstruction.
　 A diagnosis of DI-ILD caused by TMP/SMX was 
suspected when the following 3 criteria were met.  (1) 
the pulmonary lesion was detected after the adminis-
tration of TMP/SMX; (2) a diagnosis of infectious 
disease and pulmonary congestion was ruled out on 
clinical grounds; and (3) the suspected DI-ILD 
emerged or resolved,  independently of the course of 
the underlying pulmonary disease.
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Table 1　 Characteristics of the cases＊
Case Age and sex Underlying disease Purpose of Administration
Dose of 
TMP/SMX Frequency
 1 70 y.o. female Wegenerʼs granulomatosis Prophylaxis 80/400mg once a week
 2 71 y.o. female Interstitial pneumonia Prophylaxis 80/400mg once a week
 3 67 y.o. male Interstitial pneumonia Prophylaxis 80/400mg once a day
 4 73 y.o. female Interstitial pneumonia Prophylaxis 80/400mg once a day
 5 60 y.o. female Dermatomyositis Prophylaxis 80/400mg once a day
 6 77 y.o. female Interstitial pneumonia Prophylaxis 80/400mg once a day
 7 84 y.o. male Acute lung injury Prophylaxis 80/400mg once a day
 8 71 y.o. male Microscopic polyangiitis Prophylaxis 80/400mg once a day
 9 73 y.o. male Interstitial pneumonia Treatment 320/1,600mg twice a day
10 84 y.o. female Interstitial pneumonia Treatment 320/1,600mg twice a day
＊TMP/SMX denotes trimethoprim/sulfamethoxazole.
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Results
　 In addition to glucocorticoid,  2 and 5 of 10 
patients received cyclophosphamide and cyclosporine,  
respectively,  for treatment of the underlying disease.  
Nine of 10 patients took TMP/SMX more than 4 
weeks after the initiation of reatment for the underly-
ing disease.  When TMP/SMX was introduced,  no 
other medication was started at the same time.  After 
the introduction of TMP/SMX,  we found various 
ILDs on the CT scanning images of these cases.  The 
time course and the radiologic characteristics of these 
ILDs are shown in Table 2 and 3,  and in Figs.  1,  2 
and 3.
　 None of the patients had any symptoms related to 
the ILDs,  and thus we not identify the onset of the 
ILDs.  The median time point of conﬁrmation of the 
radiologic abnormality by CT scan was 11 days 
(range: 4 to 32 days) after the introduction of TMP/
SMX.  The lung lesion was detected within 14 days in 
8 of 10 cases.  After the detection of the pulmonary 
lesions,  the administration of TMP/SMX was discon-
tinued in 3 of 10 cases,  and in the other 7 cases the 
administration was continued.  In 9 of 10 cases,  the 
pulmonary lesions disappeared at between 26 days and 
90 days after introduction of TMP/SMX.  In 5 of 8 
cases for prophylaxis the pulmonary lesions disap-
peared within 56 days after introduction.  One of 2 
cases receiving TMP/SMX for the purpose of treat-
ment was left with a scar (Table 2).
　 During the observation period,  the course of the 
underlying diseases had no relation to the ILDs.  
Typical radiographic courses of the ILDs and the 
underlying diseases are shown in Figs.  4,  5 and 6.  
No abnormality related to the underlying lung disease 
was found by chest radiography in the 8 cases (cases 
183Suspected of Drug-induced Lung DiseaseJune 2010
Table 2　 Time course of the abnormality＊
Case Detection of abnormality after introduction of TMP/SMX Course of the radiographic abnormality
Dose of PSL at 
the onset
 1 19 days Disappeared 48 days after introduction 40mg
 2  4 days Disappeared 63 days after introduction 30mg
 3 11 days Disappeared 33 days after introduction 30mg
 4 32 days Disappeared 56 days after introduction 30mg
 5 12 days Disappeared 39 days after introduction 30mg
 6 14 days Disappeared 90 days after introduction 20mg
 7 14 days Disappeared 26 days after introduction 30mg
 8  8 days Disappeared 30 days fater introduction 60mg
 9  5 days Disappeared 60 days after introduction 10mg
10  6 days Scarring 50 days after introduction 10mg
＊PSL denotes prednisolone.
Table 3　 Features of the abnormal radiologic ﬁndings
Case Distribution Radiographic abnomality
 1 Outer zone of left S3 Equivocal patchy area of ground glass opacity with air-bronchiologram.
 2 Middle zone of left S1＋2 Small area of ground glass opacity delineated by airway and vessel.
 3 Middle zone of right S1,  2,  3 Equivocal patchy area of ground glass opacity
 4 Middle and outer zone of right S2,  S3 Patchy area of inﬁltration.  Weak lesions have obscure border and strong ones have clear border.
 5 Middle zone of left S1＋2 Irregular-shaped opaciﬁcation around bronchovascular bundle
 6 Outer zone of right S4 Equivocal patchy area of ground glass opacity with air-bronchiologram
 7 Middle and outer zone of left S3 Equivocal patchy area of inﬁltration
 8 Outer zone of bilateral S9,  S10 Well-demarcated band and nodular shadow
 9 Middle and outer zone of bilateral S2 Equivocal inﬁltration
10 Middle and outer zone of bilateral S1, 2 Widespread inﬁltration,  partially with clear border and in other part with equivocal border.
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1 to 7,  and 9) because pulmonary lesions were not 
severe.  In analyzing the radiologic image patterns of 
the CT scan obtained from all 10 cases,  7 cases 
showed pulmonary lesions in the ipsilateral lungs,  and 
3 cases showed pulmonary lesions in both lungs.  In the 
7 cases patients for whom the lesions were limited to 
the ipsilateral lungs,  the lesions were localized to the 
upper lobes in 6 cases,  and to the middle lobe in one.  
Bilateral lesions were localized to the upper lobes in 
2 cases,  and to the lower lobe in one.  To classify the 
pulmonary lesions according to the lung zones,  in 3 
cases they were distributed to the middle zone,  in 4 
cases they were spread from the middle to outer 
zones,  and in the other 3 cases they were found in the 
outer zone (Table 3,  Figs.  1,  2 and 3).
　 Concerning the relation to the pulmonary second-
ary lobule,  we could not discern any relation between 
these pulmonary lesions and secondary lobule,  because 
the borders of the lesions were often obscure,  or the 
lesions were often localized in the middle zone of the 
lung,  where it was diﬃcult to identify the secondary 
pulmonary lobule.
　 In regard to the relation between the amount of 
TMP/SMX administered and the severity of the pul-
monary lesions,  the patient given the lowest dosage 
had the weakest radiologic abnormality (case 1),  and 
the patient given the highest dosage had the strongest 
radiologic ﬁndings.
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Fig. 1　 Panel A shows patchy shadows in the outer zone of left 
S3,  as observed in case 1.  Panel B shows a small increase in 
density in the middle zone of left S1＋2,  as observed in case 2.  
Panel C shows inﬁltration in the middle zone of right S1,  S2,  S3,  
as observed in case 3.  Panel D shows patchy areas of inﬁltration in 
the middle and outer zone of right S2,  S3,  as observed in case 4.  
The weak lesions had obscure borders and the strong ones had 
clear border.  Ovals indicate abnormal shadows that appeared after 
the administration of TMP/SMX.
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Fig. 2　 Panel A shows irregular-shaped inﬁltration in the middle 
zone of left S1＋2,  as observed in case 5.  Panel B shows patchy 
inﬁltration in the outer zone of right S5,  as observed in case 6.  
Panel C shows patchy area of inﬁltration in the left S3,  as observed 
in case 7.  Panel D shows the well-demarcated band and nodular 
shadows in the outer zone of left S9,  S10,  as observed in case 8.  
This case had bilateral pulmonary inﬁltration.  Ovals indicate abnor-
mal shadows that appeared after the administration of TMP/SMX.
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Discussion
　 There have been few case reports on ILDs during 
the administration of TMP/SMX.  In this article,  we 
studied clinical and radiographic features of pulmo-
nary lesions during TMP/SMX administration,  while 
the patients were receiving treatment for underlying 
diﬀuse lung disease.  In these patients,  various ILDs 
were found after the introduction of TMP/SMX,  
which were not present at the beginning of the treat-
ment for the underlying disease.
　 Because none of these cases had any clinical symp-
toms associated with drug-induced pulmonary injury,  
we could not observe the onset of the ILDs precisely.  
But the fact that pulmonary abnormalies were detected 
on the CT scan within 14 days after introduction of 
TMP/SMX in 8 of 10 cases indicates that these ILDs 
tended to occur relatively earlier,  which is consistent 
with the former report of DI-ILD caused by TMP/
SMX [6].
　 As to the radiographic features of the ILDs 
observed in this study,  these ILDs are characterized 
as patchy shadows distributed from the middle to 
outer zones,  mainly in the upper lungs.  The second-
ary pulmonary lobule as deﬁned by Miller refers to the 
smallest unit of lung structure marginated by connec-
tive tissue septa [11].  On CT scanning,  it is possible 
to some extent to assume the histopathologic pattern 
185Suspected of Drug-induced Lung DiseaseJune 2010
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Fig. 4　 Panels A and B show the HRCT ﬁndings in case 7 on the 
day of TMP/SMX introduction,  panels C and D show the HRCT 
ﬁndings at 14 days after TMP/SMX introduction,  and panels E and 
F show the ﬁndings at 40 days.  Panels A and B show abnormal 
shadows of the underlying acute lung injury.  Panels C and D show 
the emergence of irregular inﬁltration in the left upper lobe,  and the 
improvement of consolidation in the left lower lobe.  In panels E and 
F,  the previously emerged inﬁltration in the left upper lobe has 
almost disappeared,  while the diﬀuse inﬁltration in the left lower 
lobe and ground glass opacity seen in the dorsal part of the left 
upper lobe have worsened.
B
A
Fig. 3　 Panel A shows inﬁltration in the middle and the outer 
zone of right S2,  as observed in case 9.  Panel B shows wide-
spread inﬁltration in the middle and the outer zone of left S3,  as 
observed in case 10.  Cases 9 and 10 both showed bilateral pulmo-
nary inﬁltration.  Ovals indicate abnormal shadows that appeared 
after the administration of TMP/SMX.
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Fig. 6　 Panels A and B show the HRCT ﬁndings in case 10 one 
day before TMP/SMX introduction,  panels C and D show the 
HRCT ﬁndings 6 days after TMP/SMX introduction,  and panels E 
and F show the ﬁndings 50 days after introduction.  The diﬀuse 
inﬁltration in the periphery of the left upper lobe in panel A and 
small nodular shadows in the left lower lobe in panel B represent 
the underlying interstitial pneumonia.  The irregular inﬁltration in the 
middle and the outer zone of left S1＋2 have emerged in panel C,  
while the underlying reticulonodular shadow in the left lower lobe 
remained stable in panel D.  This patient received TMP/SMX for 8 
days and then the medication was discontinued because of sus-
pected drug-induced interstitial lung disease.  Panel E shows that 
the previously emerged inﬁltration in the left upper lobe resolved but 
left scarring,  and panel F shows the slight worsening of the reticu-
lar opacity in the left lower lobe.
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Fig. 5　 Panels A and B show the HRCT ﬁndings in case 9 one 
day before TMP/SMX introduction,  panels C and D show the 
HRCT ﬁndings 5 days after TMP/SMX introduction,  and panels E 
and F show the ﬁndings 60 days after introduction.  The diﬀuse 
inﬁltration in the periphery of the right upper lobe in panel A and the 
reticular opacity in the right lower lobe in panel B represent the 
underlying interstitial pneumonia.  This patient received TMP/SMX 
for 3 days and then the medication was discontinued because of 
nausea.  Irregular inﬁltration in the middle and the outer zone of right 
S2 has emerged in panel C,  while the underlying reticular opacity 
in the right lower lobe remains stable in panel D.  The previously 
emerged inﬁltration in the right upper lobe has disappeared in panel 
E,  and the reticular shadow in the right lower lobe is improved in 
panel F.
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of the lesion from its radiologic imaging pattern in 
relation to the anatomy of the pulmonary secondary 
lobule.  And it is easier to recognize a secondary lob-
ule that is on the periphery of the lung,  and more 
diﬃcult for that in middle zone or inner zone of the 
lung.  Most of the present cases that showed abnormal 
ﬁndings had lesions with obscure border,  or lesions in 
the middle zone where pulmonary secondary lobules 
are diﬃcult to identify,  and thus we could not descern 
the relation between the ILDs and secondary lobules 
in these cases,  and consequently it was not possible to 
assume the histopathologic pattern of these lesions.
　 Radiographically,  these ILDs were so character-
less that neither infectious disease nor exacerbation of 
the underlying disease seemed an appropriate diagno-
sis.  Because the diagnoses of infectious disease and 
exacerbation of the underlying disease were excluded 
on clinical grounds and radiographically,  the alterna-
tive diagnosis of DI-ILDs caused by TMP/SMX was 
suspected in these cases.
　 In 7 of 8 patients (cases 1 to 7) to whom prophy-
lactic administration was given,  the chest abnormal 
shadow was relieved despite the continuous adminis-
tration of TMP/SMX.  These were considered cases 
of “transient pulmonary inﬁltration”,  which is recog-
nized as a chest radiographic abnormality without 
signiﬁcant clinical symptoms and occurring for only a 
short period of time.  Seven of the 8 patients who 
received a prophylactic dose of TMP/SMX showed 
ILDs in the ipsilateral lungs,  and in 6 of these cases 
the ILDs appeared in the upper lobe.  From this 
observation,  a patient receiving a prophylactic dose of 
TMP/SMX will tend to show a triﬂing shadow in the 
upper lobe.  Both of the patients who were treated 
with a therapeutic dose of TMP/SMX showed abnor-
malities in the bilateral upper lobe.  Comparing this 
ﬁnding with that of the abnormalities found in the 
patients taking a prophylactic dose,  there would seem 
to be some relation between the dosage of TMP/SMX 
and the intensity of the pulmonary lesion.
　 In conclusion,  we studied a range of ILDs found by 
chest CT imaging after TMP/SMX administration for 
patients with underlying diﬀuse pulmonary diseases.  
Considering the mild clinical course of these cases,  
and the absence of CT ﬁndings indicative of infectious 
diseases or exacerbation of the underlying diseases,  
we suspected that these lesions were DI-ILDs caused 
by TMP/SMX.
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